Compare Alcon AG (ALC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Neurocrine Biosciences Inc — how do they compare? Alcon AG trades at $72.61 (market cap $36.44B), while Neurocrine Biosciences Inc trades at $151.75 (market cap $16.46B). The key difference: Alcon AG is far larger — about 2.2× Neurocrine Biosciences Inc's market cap, and Alcon AG pays a 0.48% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| ALC | NBIX | |
|---|---|---|
Market Cap | $36.44B | $16.46B |
Sector | Health | Health |
52-Week High | $90.12 | $185.50 |
52-Week Low | $62.02 | $123.10 |
Enterprise Value | $40.28B | $16.48B |
Dividend Yield | 0.48% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
